Zhaojuan Yang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9599538/publications.pdf

Version: 2024-02-01

17	502	12 h-index	18
papers	citations		g-index
18	18	18	799
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	ETV4 potentiates nuclear YAP retention and activities to enhance the progression of hepatocellular carcinoma. Cancer Letters, 2022, , 215640.	3.2	9
2	The deubiquitinase USP16 functions as an oncogenic factor in K-RAS-driven lung tumorigenesis. Oncogene, 2021, 40, 5482-5494.	2.6	6
3	Fluorinated Carbon Nanotube Superamphiphobic Coating for High-Efficiency and Long-Lasting Underwater Antibiofouling Surfaces. ACS Applied Bio Materials, 2021, 4, 6351-6360.	2.3	14
4	USP12 downregulation orchestrates a protumourigenic microenvironment and enhances lung tumour resistance to PD-1 blockade. Nature Communications, 2021, 12, 4852.	5 . 8	18
5	Deubiquitination of the repressor E2F6 by USP22 facilitates AKT activation and tumor growth in hepatocellular carcinoma. Cancer Letters, 2021, 518, 266-277.	3.2	11
6	Requirement for POH1 in differentiation and maintenance of regulatory T cells. Cell Death and Differentiation, 2019, 26, 751-762.	5.0	9
7	Targeting POH1 inhibits prostate cancer cell growth and enhances the suppressive efficacy of androgen deprivation and docetaxel. Prostate, 2019, 79, 1304-1315.	1.2	17
8	POH1 contributes to hyperactivation of TGF- \hat{l}^2 signaling and facilitates hepatocellular carcinoma metastasis through deubiquitinating TGF- \hat{l}^2 receptors and caveolin-1. EBioMedicine, 2019, 41, 320-332.	2.7	28
9	USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis. Oncogene, 2019, 38, 2405-2419.	2.6	73
10	POH1 deubiquitinates pro-interleukin- \hat{l}^2 and restricts inflammasome activity. Nature Communications, 2018, 9, 4225.	5.8	30
11	USP16 Downregulation by Carboxyl-terminal Truncated HBx Promotes the Growth of Hepatocellular Carcinoma Cells. Scientific Reports, 2016, 6, 33039.	1.6	27
12	POH1 deubiquitylates and stabilizes E2F1 to promote tumour formation. Nature Communications, 2015, 6, 8704.	5.8	89
13	SIP1 is a downstream effector of GADD45G in senescence induction and growth inhibition of liver tumor cells. Oncotarget, 2015, 6, 33636-33647.	0.8	14
14	Transcription factor KLF9 suppresses the growth of hepatocellular carcinoma cells in vivo and positively regulates p53 expression. Cancer Letters, 2014, 355, 25-33.	3.2	61
15	GADD45 proteins: roles in cellular senescence and tumor development. Experimental Biology and Medicine, 2014, 239, 773-778.	1.1	29
16	The combinatory effects of PPAR-Î ³ agonist and survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cells. International Journal of Molecular Medicine, 2014, 34, 262-268.	1.8	22
17	Transient mTOR Inhibition Facilitates Continuous Growth of Liver Tumors by Modulating the Maintenance of CD133+ Cell Populations. PLoS ONE, 2011, 6, e28405.	1.1	44